Get started
Author

David Vicente

Observed names: D Vicente, D. Vicente, David Vicente Baz
ORCID: 0000-0002-6052-0070
Observed ORCID: 0000-0002-6052-0070
OpenAlex ID: A5009437498
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · James Chih-Hsin Yang, Dae Ho Lee, et al. · Journal of Clinical Oncology · 237
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
2024 · S. Lu, M.-J. Ahn, et al. · Annals of Oncology · 38
PDF
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024 · Niels Reinmuth, Oscar Juan-Vidal, et al. · Clinical Cancer Research · 13
Tele-Rehabilitation and Tele-Psychological Support for People with Cancer across Nine European Countries: Three Multicentre Randomised Controlled Pilot Trials
2026 · Vittorio Castaldo, Irene Terrenato, et al. · SSRN Electronic Journal
Remote physiologic and behavioral monitoring to predict early treatment response in metastatic cancer: High-Definition Oncology study (HDOs) preliminary results.
2025 · Leire Paz-Arbaizar, María Sauras, et al. · Journal of Clinical Oncology
Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024 · Niels Reinmuth, Oscar Juan-Vidal, et al.
Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024 · Niels Reinmuth, Oscar Juan-Vidal, et al.
Supplementary Data 1 from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
2024 · Niels Reinmuth, Oscar Juan-Vidal, et al.
EE193 Lorlatinib as a First-Line Treatment for ALK+ Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Spain
2022 · M Presa, D Vicente, et al. · Value in Health
PDF
Works count: 9
Citation count: 288
H-index: 3
I10-index: 3
Year
Topic
Type